Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ABBV crawled time : 16:20 save search
AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints
Published: 2023-10-15 (Crawled : 16:20) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
| Email alert
Add to watchlist
skyrizi disease study
AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy
Published: 2023-03-18 (Crawled : 16:20) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
| Email alert
Add to watchlist
il-17 skyrizi abbvie psoriasis response therapy results study
Health Equity Report Card Pilot Project to Help Close the Care Gap Highlighted on World Cancer Day
Published: 2023-02-04 (Crawled : 16:20) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
| Email alert
Add to watchlist
day care report health pilot cancer
Female contraceptive market size to grow by USD 5,142.22 million: Personal products industry is the parent market - Technavio
Published: 2022-12-10 (Crawled : 16:20) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
| Email alert
Add to watchlist
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
| Email alert
Add to watchlist
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
| Email alert
Add to watchlist
RBGLY | $10.29 -2.05% 1.4M
|
Manufacturing
| Email alert
Add to watchlist
RBGPF | $52.0 6.46% 34K
|
Consumer Non-Durables
| Email alert
Add to watchlist
contraceptive market
AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress
Published: 2022-06-11 (Crawled : 16:20) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
| Email alert
Add to watchlist
cd20 duobody trial results
Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights
Published: 2022-03-10 (Crawled : 16:20) - investor.assemblybio.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 1.15%
H: 0.0%
C: 0.0%
BGNE | $131.94 0.06% 0.06% 130K
|
Health Technology
|
| O: 3.43%
H: 0.0%
C: 0.0%
ASMB | $12.95 0.23% 0.23% 17K
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
financial results report bioscience results
New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition
Published: 2021-07-25 (Crawled : 16:20) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
| Email alert
Add to watchlist
treatment eye potential presbyopia
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.